MedTrace Logo

Efficacy and Safety of Doravirine in the Rapid Initiation

NCT07357584 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-01-22

No results posted yet for this study

Summary

Protocol title: "Efficacy and safety of doravirine in the rapid initiation of highly active antiretroviral therapy (HAART) in HIV-1positive patients without prior treatment."

Conditions

Interventions

DRUG

Doravirine / lamivudine/ Tenofovir Disoproxil Oral Tablet

Pharmaceutical form: Oral tablets Unit dose concentration/dose level(s): 100/300/245 mg Administration instructions: Take one tablet once a day

Sponsors & Collaborators

  • MSD Pharmaceuticals LLC

    collaborator INDUSTRY

  • Fundacion IDEAA

    collaborator OTHER

  • Fundación Huésped

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-13
Primary Completion
2028-01-13
Completion
2028-01-13

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07357584 on ClinicalTrials.gov